Dr.

Reddys Laboratories is leading pharmaceutical company with presence in over 100

countries. It manufactures a range of products such as Active pharmaceutical ingredients,
Generic and Branded Finished Dosages, Specialty pharmaceuticals, and Biopharmaceuticals.
The company is situated at Ameerpet, Hyderabad. :
Dr. Reddys Laboratories is leading pharmaceutical company with presence in over 100
countries. It manufactures a range of products such as Active pharmaceutical ingredients,
Generic and Branded Finished Dosages, Specialty pharmaceuticals, and Biopharmaceuticals.
The company is situated at Ameerpet, Hyderabad.

History: The company was incorporated on November 2, 1984, by Dr. Anji Reddy and his
associates who were also the promoters of Standard Organics Limited. It was based on a bulk
activities business he had founded in the 1970s, in order to extend into the production of
drug formulation. It was established with an initial capital outlay of $40,000 of his own
backed by a bank loan for $120,000. Two years later, in 1986, it got listed in the Bombay
Stock Exchange. :
History: The company was incorporated on November 2, 1984, by Dr. Anji Reddy and his
associates who were also the promoters of Standard Organics Limited. It was based on a bulk
activities business he had founded in the 1970s, in order to extend into the production of drug
formulation. It was established with an initial capital outlay of $40,000 of his own backed by a
bank loan for $120,000. Two years later, in 1986, it got listed in the Bombay Stock Exchange.

In 1987 obtained its 1st USFDA approval for Ibuprofen API and started its formulation
operations. In 1997, it became the 1st Indian pharmaceutical company to out- license an
original molecule when it licensed anti-diabetic molecule DRF 2593 to Novo Nordisk. In 2000,
became the 1st Asia Pacific pharmaceutical company outside Japan, to be listed on the NEW
YORK STOCK EXCHANGE. :
In 1987 obtained its 1st USFDA approval for Ibuprofen API and started its formulation
operations. In 1997, it became the 1st Indian pharmaceutical company to out- license an
original molecule when it licensed anti-diabetic molecule DRF 2593 to Novo Nordisk. In 2000,
became the 1st Asia Pacific pharmaceutical company outside Japan, to be listed on the NEW
YORK STOCK EXCHANGE.

Vision and MissionVision: To become a discovery ruled global pharmaceutical company with
a core purpose of helping people lead healthier lives.Mission: To be first Indian
Pharmaceutical company that successfully takes its products from discovery to commercial
launch globally. :
Vision and MissionVision: To become a discovery ruled global pharmaceutical company with a
core purpose of helping people lead healthier lives.Mission: To be first Indian Pharmaceutical
company that successfully takes its products from discovery to commercial launch globally.

SWOT Analysis:Strength: - Wholly owned subsidiaries in US and Europe. Joint ventures in

China and South Africa. -Market pharmaceuticals products in 115 countries. :
SWOT Analysis:Strength: - Wholly owned subsidiaries in US and Europe. Joint ventures in China
and South Africa. -Market pharmaceuticals products in 115 countries.

-Contributes to companys high profit margin of around 34% of sales. -6120 employees
worldwide including 323 are dedicated towards new drug discovery research.- Manufactures
and market over 250 medicines targeting a wide range of therapies. :
-Contributes to companys high profit margin of around 34% of sales. -6120 employees
worldwide including 323 are dedicated towards new drug discovery research.- Manufactures
and market over 250 medicines targeting a wide range of therapies.

Weakness: -High amount of revenues from overseas. -Over reliance on partnerships.- Lack of
resources similar to US and Europe based competitors to develop a drug to marketing stage. Lack of patent legislation in India horns sales in its products. :
Weakness: -High amount of revenues from overseas. -Over reliance on partnerships.- Lack of
resources similar to US and Europe based competitors to develop a drug to marketing stage. Lack of patent legislation in India horns sales in its products.

Opportunities: -Takes a molecule from its pipeline all the market place cost- effectively.Domestic Genetic drugs market. -Buy back of the integrated drug development company
from ICICI ventures and Citigroup. :

Opportunities: -Takes a molecule from its pipeline all the market place cost- effectively.Domestic Genetic drugs market. -Buy back of the integrated drug development company from
ICICI ventures and Citigroup.

Threats: -Needs to give FDA approval for all sources and products.- Products have to pass
strictly FDA trials before going to market, which can be costly and time consuming.Competitors from US and European countries. -Lost the case against Pfizer for the use of
generic form of Norvasc drug, legal cost of $10 million and loss of market opportunities. :
Threats: -Needs to give FDA approval for all sources and products.- Products have to pass
strictly FDA trials before going to market, which can be costly and time consuming.Competitors from US and European countries. -Lost the case against Pfizer for the use of
generic form of Norvasc drug, legal cost of $10 million and loss of market opportunities.

:
Products: Active Pharmaceutical Ingredients (API)Custom Pharmaceuticals ServicesGeneric
DosagesBranded Dosages (such as- Omez, Nise, Stamlo, Ciprolet, Enam, Ketorol).

Branches:It has limited branches in Hyderabad.- DBR Diagnostic Centre, Kapra.-Dr. Reddys
Laboratories Ltd, Kapra.-Pragathi Diagnostic , Kapra.- SL Diagnostic and Speciality Clinic,
Kapra. :
Branches:It has limited branches in Hyderabad.- DBR Diagnostic Centre, Kapra.-Dr. Reddys
Laboratories Ltd, Kapra.-Pragathi Diagnostic , Kapra.- SL Diagnostic and Speciality Clinic, Kapra.

Turnover:About 6900 crores from single manufacturing units in Hyderabad. 39% rise in its 1st
quarter 2009-2010, revenues at Rs. 1,818 crores, against Rs. 1,500 crores in the same previous
year. :
Turnover:About 6900 crores from single manufacturing units in Hyderabad. 39% rise in its 1st
quarter 2009-2010, revenues at Rs. 1,818 crores, against Rs. 1,500 crores in the same previous
year.

Growth over 20 yearsThe company is growing by 39% and improving EBITA by 50%. The
profitability has rose by 44%. :
Growth over 20 yearsThe company is growing by 39% and improving EBITA by 50%. The
profitability has rose by 44%.

Dr.Reddys Laboratories was founded in 1984, with a capital of US $40,000 in cash and US $120,000 in
bank loan

In fact, it is this spirit of entrepreneurship that has shaped the company to become what it is
today
Today, the company with revenues of US $446 m, in fiscal year 2005, is Indias second largest
pharmaceutical company and the youngest among its peer group
Dr. Reddys started its drug discovery programme in 1993 and within three years it achieved
its first breakthrough by out licensing an anti-diabetes molecule to Novo Nordisk in March
1997
With this very small but significant step, the Indian industry went through a paradigm shift in
its image from being known as just copycats to innovators!
Through its success, Dr. Reddys pioneered drug discovery in India

Today, the company manufactures and markets API (Bulk Actives), Finished Dosages and
Biologics in over 100 countries worldwide, in addition to having a very promising Drug
Discovery Pipeline